Controversial test 'can stop prostate cancer'
Steve Connor is the Science Editor of The Independent. He has won many awards for his journalism, including five-times winner of the prestigious British science writers’ award; the David Perlman Award of the American Geophysical Union; twice commended as specialist journalist of the year in the UK Press Awards; UK health journalist of the year and a special merit award of the European School of Oncology for his investigative journalism. He has a degree in zoology from the University of Oxford and has a special interest in genetics and medical science, human evolution and origins, climate change and the environment.
Monday 30 July 2012
Three times as many men would end up with advanced prostate cancer if a controversial blood test widely criticised for unreliable diagnoses did not exist, a study suggests.
The prostate-specific antigen (PSA) test is commonly used in Britain and other countries to identify men at risk of prostate cancer. But critics argue that it frequently results in aggressive treatments which carry a risk of serious side-effects, even though the cancer may be benign and harmless.
Concerns about the accuracy of the PSA test have led to it being used on a case-by-case basis, usually involving men who have already complained of symptoms, rather than as a general screening.
The study, published in the online journal Cancer, analysed the incidence of advanced prostate cancer in the early 1980s, before the PSA test was introduced. It found that the test has resulted in a significant improvement in the early detection of cancers that would otherwise spread to other parts of the body.
The scientists said that doing away with the PSA test would likely result in three times as many men than at present developing an advanced stage of the disease, which spreads beyond the prostate gland before being diagnosed.
The study estimated that about 17,000 American men each year are being saved from progressing to advanced prostate cancer by the early detection of their disease with the help of the PSA test.
“Not doing the PSA test will result in many men presenting with far more advanced prostate cancer. And almost all men with metastasis at diagnosis will die from prostate cancer,” said Edward Messing of the University of Rochester Medical Centre in New York, a co-author of the study.
The test measures the amount of a protein called prostate-specific antigen in the bloodstream. Prostate cancer cells and normal prostate cells both produce the antigen, which varies in concentration between individuals and age groups, factors which make a definitive diagnosis difficult.
Prostate cancer is newly diagnosed in 41,000 British men each year and kills more than 10,000 patients annually. It is the fourth most common cancer in the UK and the most common in men, accounting for a quarter of all new cases of male cancers.
The incidence of prostate cancer has increased significantly in recent years, helped by better diagnosis and reporting, partly as a result of using the PSA blood test.
Medical authorities in both the US and Britain have advised against using the PSA test for general population screening because they say it would lead to unnecessary treatment of non-aggressive forms of the cancer in men who as a result would be at risk of side-effects, such as incontinence or erectile dysfunction.
Owen Sharp, chief executive of the charity Prostate Cancer UK, said: “Although recent research does suggest that screening for prostate cancer may reduce the number of deaths from this disease, we still believe that the potential negative impact of screening outweighs its potential positives. As screening can potentially lead to over-diagnosis and unnecessary treatment we do not currently support the introduction of a national screening programme.”
- 1 Is Gideon Levy the most hated man in Israel or just the most heroic?
- 2 Students offered grants if they tweet pro-Israeli propaganda
- 3 Satellite full of sexually experimental geckos adrift in space, Russia loses control of mission
MH17 crash: Investigators discover more human remains and 'huge section of plane'
Susan Sarandon on David Bowie romance: 'He's worth idolising'
Students offered grants if they tweet pro-Israeli propaganda
A day in the life of Vladimir Putin: The dictator in his labyrinth
Exclusive: Cameron’s ‘Big Society’ in tatters as charity watchdog launches investigation into claims of Government funding misuse
The 'scroungers’ fight back: The welfare claimants battling to alter stereotypes
Arizona execution lasts two hours as killer Joseph Wood left 'snorting and gasping' for air
Malaysia Airlines MH17 crash: Ukrainian military jet was flying close to passenger plane before it was shot down, says Russian officer
Malaysia Airlines MH17 crash: Massive rise in sale of British arms to Russia
Malaysia Airlines MH17 crash: victims’ bodies bundled in black bags and loaded onto trains
John Barrowman praised for Commonwealth Games opening ceremony gay kiss
£600 - £650 per day: Orgtel: Conduct Risk Liaison Manager - Banking - London -...
Highly Attractive Package: Austen Lloyd: CITY - COMMERCIAL LITIGATION - GLOBAL...
£65000 - £75000 per annum + Benefits: Progressive Recruitment: The client is a...
£40000 - £45000 per annum: Ashdown Group: A well-established software house ba...